Will Pelage include Norwood 7 hair loss in PP405 phase 3 trials to see its true regenerative potential? Chat 1/10/2026
Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity PP405 vs Hair Cloning – Which Would Be Better for NW7 to NW1?
PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.
community UCLA scientists found a molecule — PP405 — that wakes up sleeping hair follicles and tells them, “Do your job.”
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
community The Cure isn't 5 years away; it's already here.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
community I hope ET-02 or PP405 will be released in the next 4-5 years
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
community VDPHL01 phase-2/3 results comparison
The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.
Related Research
6 / 6 resultsresearch Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Abstracts from the 17th Congress of the European Society for Dermatology and Psychiatry
The congress showed that psychological therapy can help skin condition patients, social media affects acne stigma, education improves atopic dermatitis, and patient satisfaction in dermatology is high, especially with good doctor engagement.
research Differences in Demographic and Clinical Characteristics Among Subtypes of Female Pattern Hair Loss
In this study, the Hamilton-Norwood subtype of female pattern hair loss was associated with early onset and polycystic ovary syndrome, while the Ludwig pattern was more common overall.
research Evaluating the Role of the Gabrin Sign in Predicting COVID-19 Severity Among Patients with Androgenic Alopecia
This study found that patients with androgenetic alopecia had significantly higher COVID-19 severity compared to matched controls, suggesting a potential link between androgen pathways and disease severity. The authors suggest further research to validate this hypothesis and explore antiandrogen treatments for managing COVID-19 severity.
research Is there a relationship between androgenic alopecia and benign prostatic hyperplasia?
This study found no relationship between androgenic alopecia and parameters such as PSA level, IPSS, and prostate volume in men over 50.